Expression of p16 and VEGF in Breast Cancer Tissue and Their Clinical Significance

Objective To investigate the expression of p16 and VEGF in breast cancer and their correlation with clinicopathological parameters of breast cancer and the patients' prognosis. Methods Expressions of p16 and VEGF were determined in 53 breast cancer tissues with SABC immunohistochemical method, and clinic pathological data of the patients were collected and used to make statistical analysis. Results Positive rates of p16 and VEGF in breast cancer were 54 7%(29/53) and 79 25%(42/53), respectively. p16 expression was not associated with patient's age, tumor size, menopause, and expression of ER and PR (P0 05). A negative correlation was found between p16 expressions and the histological grade, clinical TNM stage, lymph-node metastasis and 5-years survival rate(P0 05). VEGF expression was not associated with patient's age, tumer size, menopause, expression of ER and PR, TNM stage and 5-years survival (P0 05), but associated with histological grade and lymph-node metastasis(P0 05). Conclusions The expression of p16 and VEGF was related to local invasion and lymph-node metastasis of breast carcinoma, and they could be used as a biologic marker of breast cancer. p16 may serve as an important indicator to estimate prognosis of the patients with breast cancer.